Compare Levi Strauss & Co. (LEVI) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Oscar Health Inc — how do they compare? Levi Strauss & Co. trades at $22.54 (market cap $8.75B), while Oscar Health Inc trades at $29.25 (market cap $8.63B). The key difference: Levi Strauss & Co. and Oscar Health Inc are close in size by market cap, and Levi Strauss & Co. pays a 2.81% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| LEVI | OSCR | |
|---|---|---|
Market Cap | $8.75B | $8.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $32.18 |
52-Week Low | $17.92 | $10.85 |
Enterprise Value | $10.07B | $4.99B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $22.57, down 4.32% amid a recent cybersecurity breach disclosure. The stock maintains strong fundamentals with a 9.66% net margin and 29.31% ROE, supported by three consecutive quarterly earnings beats. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions. Analyst consensus remains strongly bullish with a $27.88 price target representing 23.5% upside potential.
Despite near-term cybersecurity concerns, Levi's demonstrates robust DTC growth and digital transformation success. The company's raised 2026 outlook and dividend increase signal confidence, though execution risks and tariff pressures warrant monitoring. Current valuation at 16.24 P/E offers reasonable entry for long-term investors seeking exposure to the iconic brand's turnaround story.
Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.
Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
